Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 4/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | LOX | P28300 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13875986 | 0.86 | LOXL2 (0.42) | LOXL2KMT2AKDRLOXMAPK8 | |
| SCHEMBL13876010 | 0.83 | GRM5 (0.50) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL13876045 | 0.83 | EPHX2 (0.43) | LOXL2KMT2ARAF1LMNASMN1; SMN2 | |
| SCHEMBL13875994 | 0.82 | PARP15 (0.43) | LOXL2KMT2ALMNA | |
| SCHEMBL13875998 | 0.82 | LOXL2 (0.40) | LOXL2KDRLOX | |
| SCHEMBL13875972 | 0.80 | KCNK3 (0.48) | LOXL2LOXLMNASMN1; SMN2 | |
| SCHEMBL13876011 | 0.79 | KDM4E (0.42) | LMNACYP1A2 | |
| SCHEMBL13890745 | 0.79 | LOXL2 (0.41) | LOXL2KMT2ANPSR1KDRLOX | |
| SCHEMBL13875942 | 0.79 | LMNA (0.45) | LMNA | |
| SCHEMBL13876048 | 0.78 | ABL1 (0.43) | LOXL2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099184-A1 | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | LOXL2 434/4885KMT2A 2076/4885NPSR1 3235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.